Treats homocystinuria. Sold as Cystadane. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 16, 2026, FDA lists 3 applications for Betaine (sold as Cystadane), first approved Oct 25, 1996, with 0 new uses approved and 0 published complete response letters.
| Cystadane | Part D | $1.2M | +7% | 68 |
| Betaine Anhydrous | Part D | $1.1M | +15% | 51 |
| Methyl Donor-Rich Diet in the Postpartum PeriodPostpartum Depression (PPD), Breastfeeding · Istanbul University - Cerrahpasa | Not applicable | Recruiting | Oct 21, 2026 |
| Betaine Addition to Water Loading Prior to Running ExerciseExercise, Hydration · Poznan University of Life Sciences | Not applicable | Not yet recruiting | Sep 25, 2026 |
| Effects of 5-Methyltetrahydrofolic Acid Supplementation on Maternal Health and One-Carbon Metabolism During LactationBreastfeeding · Fundació Sant Joan de Déu | Phase 1 / Phase 2 | Recruiting | Apr 2, 2026 |
| Betaine vs. Placebo for Serologically Diagnosed Metabolic Dysfunction-associated Steatohepatitis (MASH)MASH - Metabolic Dysfunction-Associated Steatohepatitis · Southern California Institute for Research and Education | Phase 2 | Not yet recruiting | Dec 10, 2025 |
| Pharmacokinetic Assessment of Betaine Supplementation in Lactating MothersBreast Milk Fortifier Supplements · Fundació Sant Joan de Déu | Not applicable | Active, not recruiting | Nov 24, 2025 |
| Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older AdultsAging, Frailty · Scott Silveira | Not applicable | Recruiting | Aug 27, 2025 |
| Exploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune GastritisAutoimmune Gastritis · Second Affiliated Hospital, Zhejiang University, School of Medicine | Not applicable | Recruiting | Mar 18, 2025 |
| The Therapeutic Effect of Betaine in SyringomyeliaSyringomyelia · Xuanwu Hospital, Beijing | Phase 2 | Recruiting | Mar 13, 2024 |
| Oct 25, 1996 | CystadaneNDA 20576 · New molecular entity | Recordati Rare | 8 | Marketed |
| Nov 23, 2021 | BetaineANDA 214864 | Novitium Pharma | 0 | Marketed |
| Jan 28, 2022 | BetaineANDA 210508 | Eton | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA